Events Archives - Page 34 of 128

11 minute read

Events
News

MeiraGTx Announces An Oral Presentation And Eight Posters At The European Society Of Gene And Cell Therapy 2023 Annual Congress

October 24, 8:34 AM

MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight posters and deliver one oral presentation at the European Society of

MGTX

5 minute read

CymaBay Presents Results On The Potential Of Seladelpar In Treatment Of Patients With Primary Biliary Cholangitis At ACG 2023

By Happy Mohamed

October 23, 4:11 PM

Cholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated with seladelpar A second presentation of baseline trial data

CBAY

5 minute read

Reported Earlier, Alkermes Presents First Clinical Data For Orexin 2 Receptor Agonist ALKS 2680 At World Sleep Congress

By Benzinga Newsdesk

October 23, 10:45 AM

— Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 —— ALKS 2680 Was Generally Well Tolerated at All

ALKS

4 minute read

Bolt Biotherapeutics Presents Updated Clinical Data From Phase 1 Dose-Escalation Trial Of BDC-1001 As Monotherapy And In Combination With Nivolumab In HER2-Expressing Tumors At ESMO 2023 Congress

By Benzinga Newsdesk

October 23, 10:32 AM

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional patients with

BOLT

5 minute read

CEL-SCI Corporation Announces 5-Year Head & Neck Cancer Survival Increased From 45% To 73% In Co’s Target Population, Cutting Risk Of Death In Half, As Presented At Leading Cancer Conference ESMO 2023

By Happy Mohamed

October 23, 9:16 AM

Target patient population for regulatory submissions finalized: Patients with low PD-L1, in contrast tocurrent checkpoint inhibitors which work best with high PD-L1. Addressing unmet need in ~145,000 head and

CVM

3 minute read

Galecto Presents Updated Clinical Data At ESMO Congress 2023 And Provides Update On Phase 1b/2a GALLANT-1 Trial

By Happy Mohamed

October 23, 8:14 AM

Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today presented a poster with new and encouraging clinical data, including two

GLTO

6 minute read

Ambrx Announces ARX517, A PSMA-Targeted ADC, Demonstrates 52% PSA50 (≥50% Reduction) And A Highly Differentiated Safety And PK Profile In Patients With mCRPC, Who Progressed On Multiple FDA-Approved Treatments

By Happy Mohamed

October 23, 8:10 AM

Newly published data from the Phase 1 portion of the on-going Phase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at

AMAM

2 minute read

Voicing Opinions On Israel-Hamas Conflict: A Double-edged Sword For Businesses

By Benzinga Neuro

October 22, 1:55 PM

According to an Associated Press report, the Israel-Hamas conflict has stirred up controversy within the global business sector.

2 minute read

Events
News

ESSA Pharma Announced Data Combination Of Masofaniten Plus Enzalutamide Continues To Be Well Tolerated With Deep And Durable Reductions In PSA In Patients With Metastatic Castration-Resistant Prostate Cancer

By Charles Gross

October 21, 9:17 AM

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the

EPIX

2 minute read

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast In Primary Sclerosing Cholangitis To Be Highlighted In An Oral Late-Breaking Presentation At The Liver Meeting 2023

By Benzinga Newsdesk

October 19, 8:22 AM

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced a late-breaking

PLRX